Episode 11: Nephmadness Special! Matt Sparks and Aarushi Varshney on C3G

Episode 11

0:00-23:29

In this episode, hosts Dr. Kenar Jhaveri and Dr. Koyal Jain are joined by Dr. Matt Sparks (co-creator of NephMadness) and Dr. Aarushi Varshney to discuss the evolving landscape of C3 Glomerulopathy (C3G). The conversation highlights the shift from traditional electron microscopy-based classifications to modern immunofluorescence-based diagnosis, as well as the groundbreaking arrival of two new FDA-approved targeted therapies. The NephMadness Matchup This episode focuses on the C3G bracket pitting two critical aspects of C3G against each other: Team Diagnosis: Focusing on the challenges of distinguishing C3G from infection-related GN or monoclonal gammopathy. Team Treatment: Highlighting the new era of factor B and C3 inhibitors that are revolutionizing patient outcomes. Key Takeaways 1. Challenges in Diagnosis The "Two Orders of Magnitude" Rule: Modern diagnosis is based on immunofluorescence (IF) showing C3 deposition that is at least two orders of magnitude greater than any other immunoglobulin. C3G vs. PIGN: It can be difficult to distinguish C3G from Post-Infectious Glomerulonephritis (PIGN). Clinical clues include patient age, the persistence of low C3 levels after infection resolution, and the presence (or absence) of sub-epithelial humps on pathology. The Role of Monoclonal Gammopathy: In older patients, it is critical to rule out monoclonal gammopathy (using SPEP and free light chain assays) as a driver of complement activation. 2.

Publisher

GN in Ten

Link

share.transistor.fm/s/72477cca

Published

March 11, 2026

Duration

23 min

Format

Podcast

Category

Lifestyle · Medicine

Source

RSS feed

Host

International Society of Glomerular Disease

GI

GN in Ten

@gninten

#nephmadness #mattsparks #aarushivarshney #medicine #lifesciences

The Nile